Working... Menu

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02654483
Recruitment Status : Active, not recruiting
First Posted : January 13, 2016
Last Update Posted : November 1, 2018
Epidermolysis Bullosa Research Partnership
Menlo Therapeutics Inc.
Information provided by (Responsible Party):
Jean Yuh Tang, Stanford University

Brief Summary:
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and adults with Epidermolysis Bullosa (EB).

Condition or disease Intervention/treatment Phase
Epidermolysis Bullosa Pruritus Drug: VPD-737 Other: Placebo Phase 2

Detailed Description:

Itch is the most common complaint reported by patients with EB of all subtypes, and there is no current effective treatment. Itch often triggers scratching that creates new wounds and increases EB disease severity. This study aims to target the physiological mechanisms of pruritus (itch) in patients with EB .

Substance P is a major mediator of pruritus and binds to the receptor neurokinin-1 (NK1), which is expressed in the central nervous system and the skin.

VPD-737 (serlopitant), a novel drug that inhibits the NK1 receptor, has been shown to reduce severe itch in a previous study of 257 adult patients with chronic pruritus.

The investigators are now testing VPD-737 in 14 patients with EB in a Phase II randomized, placebo-controlled, double-blinded clinical trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Actual Study Start Date : August 31, 2016
Actual Primary Completion Date : July 27, 2018
Estimated Study Completion Date : February 2019

Arm Intervention/treatment
Experimental: 5 mg VPD-737
5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
Drug: VPD-737
VPD-737 inhibits the receptor neurokinin-1.
Other Name: Serlopitant

Placebo Comparator: Placebo
Placebo tablets to be taken daily by mouth for 56 days
Other: Placebo
Matching tablets to VPD-737 tablets without active drug

Primary Outcome Measures :
  1. Change in EB associated itch [ Time Frame: NRS recorded by subject daily, from screening visit through the end of the study ]
    Determine the efficacy of Serlopitant compared with placebo on reducing EB itch as measured by patient self-reports using a numeric rating scale (NRS) for itch severity and the Stanford EB itch questionnaire. NRS is included in the Stanford EB Itch survey.

Secondary Outcome Measures :
  1. Wound healing determination [ Time Frame: screening, month 1, month 2 ]
    Wound dimensions, including length, width, and area (in cm2), will be obtained using the Canfield system. Changes in dimensions between visits as well as changes in dimensions from baseline will be recorded.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of epidermolysis bullosa and pruritus

Exclusion Criteria:

  • Have chronic liver or renal disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02654483

Layout table for location information
United States, California
Stanford, California, United States, 94305
Sponsors and Collaborators
Jean Yuh Tang
Epidermolysis Bullosa Research Partnership
Menlo Therapeutics Inc.
Layout table for investigator information
Principal Investigator: Jean Tang, MD, PhD Stanford University

Layout table for additonal information
Responsible Party: Jean Yuh Tang, Associate Professor, Stanford University Identifier: NCT02654483     History of Changes
Other Study ID Numbers: 34182
First Posted: January 13, 2016    Key Record Dates
Last Update Posted: November 1, 2018
Last Verified: October 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Epidermolysis Bullosa
Skin Diseases
Skin Manifestations
Signs and Symptoms
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Vesiculobullous
Neurokinin A
Substance P
Neurokinin-1 Receptor Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs